Faruqi and Faruqui, LLP Logo
Share this page

Intercept Pharmaceuticals Inc. (ICPT)



Court Appoints Faruqi & Faruqi, LLP As Lead Counsel For Class Action Against Intercept Pharmaceuticals, Inc.

Faruqi & Faruqi, LLP, a leading national securities law firm, announces that it has been appointed as Lead Counsel in DeSmet v. Intercept Pharmaceuticals, Inc., et al., No. 1:17-cv-07371-LAK, a class action alleging violations of the federal securities laws against Intercept Pharmaceuticals, Inc. (“Intercept” or the “Company”) and certain of the Company’s officers and directors.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) the Company’s lead product candidate Ocaliva, a bile acid analog for the treatment of primary biliary cholangitis (“PBC”), entailed undisclosed safety risks, including death, to patients suffering from PBC; and (ii) as a result, Intercept's public statements were materially false and misleading at all relevant times.

Specifically, on September 12, 2017, Intercept issued a letter that warned physicians against overdosing patients with Ocaliva, advising them that the drug has been tied to liver injuries and death among patients suffering from PBC.  On this news, Intercept’s share price fell from $113.48 per share on September 11, 2017 to a closing price of $98.12 on September 12, 2017—a $15.36 or a 13.54% drop.

Then, on September 21, 2017, the U.S. Food and Drug Administration (“FDA”) issued a safety announcement entitled “FDA Drug Safety Communication: FDA warns about serious liver injury with Ocaliva for rare chronic liver disease,” which warned doctors about reports of multiple deaths linked to the drug.  On this news, Intercept’s share price fell from $98.12 per share on September 20, 2017 to a closing price of $73.70 on September 21, 2017—a $24.42 or a 24.89% drop.

If you purchased shares between May 31, 2016 and September 20, 2017, both dates inclusive, please contact the firm to discuss this matter with us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an email to rgonnello@faruqilaw.com.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Intercept’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Request more information now by filling out the form below.  There is no cost or obligation to you.

Contact Us

To contact Faruqi & Faruqi, LLP please call (877) 247-4292 or (212) 983-9330, or please
fill out the form below and a Firm representative will contact you.

  • Case:
    Intercept Pharmaceuticals Inc. (ICPT)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 09/27/2017

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.